[18F]Florbetazine ([18F]92) is a molecularly targeted imaging agent for Aβ protein with a novel diaryl-azine scaffold. It has shown specific binding affinity to Aβ aggregates in postmortem human AD brains and excellent brain pharmacokinetic properties with little non-specific retention in white matter in animal studies and a limited number of patients with Alzheimer's Disease (AD).
The purpose of the current study is to examine the binding properties of [18F]Florbetazine in human subjects and to compare the cortical and white matter binding with [11C]PiB or [18F]Florbetapir in the same subjects.
Imaging of the brain will be completed in healthy adult normal control participants and participants with cognitive impairment (including probable AD and dementia due to other conditions) to characterize [18F]Florbetazine uptake in the brain and its binding properties. [11C]PIB or [18F]Florbetapir PET imaging along with MRI will be completed in the same participants and the data will be compared with 18F-[18F]Florbetazine.

Start Date30 Jan 2023

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT05184088

/ RecruitingPhase 3

An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.

Start Date13 Jan 2023

Sponsor / Collaborator

Life Molecular Imaging Ltd.

[+1]

NCT05361382

/ RecruitingPhase 1IIT

Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers

The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.

Start Date23 Nov 2021

Sponsor / Collaborator

University of Pittsburgh

[+1]

100 Clinical Results associated with Florbetaben F-18

100 Translational Medicine associated with Florbetaben F-18

100 Patents (Medical) associated with Florbetaben F-18

Literatures (Medical) associated with Florbetaben F-18

01 Dec 2024·Alzheimer's & Dementia

The Association between measures of Sleepiness and Subjective Cognitive Decline symptoms in a diverse population of cognitively normal older Adults

Article

Author: Betensky, Rebecca A ; Briggs, Anthony Q ; Masurkar, Arjun V. ; Bernard, Mark A

AbstractBackgroundSubjective cognitive decline (SCD) is a preclinical stage of Alzheimer’s disease (AD), with correlations to cerebral amyloid and tau and accelerated cognitive decline. Studies have also revealed an association between sleep fragmentation and such AD biomarkers and cognitive decline, suggesting that cognitive function should be monitored in individuals experiencing excessive sleepiness. It is unclear if and how sleep dysfunction relates to SCD apart from AD biomarkers, as well as symptoms related to SCD and sleep dysfunction, such as depression. Furthermore, studies of SCD and sleep dysfunction have primarily focused on non‐Hispanic Whites. Hence, a better understanding of how sleep impacts preclinical AD risk in SCD is needed in more diverse cohorts. We investigated the cross‐sectional relationship between excessive sleepiness in cognitively normal older adults and SCD symptoms linked to cognitive domains in a cohort consisting of NHWs and Black/African Americans (B/AA).MethodThis retrospective cross‐sectional study included cognitively normal older participants (n = 147, age> 60 years, 61 B/AA, 86 NHW) evaluated at the NYU Alzheimer’s Disease Research Center. Participants underwent Uniform Data Set 3.0 psychometric testing to confirm normal cognition, Epworth Sleepiness Scale (ESS), Geriatric Depression Scale (GDS), and the Cognitive Change Index (CCI) as a measure of SCD. The CCI was further divided into subscores of non‐amnestic (i.e. executive) and amnestic domains (i.e. memory). Participants underwent amyloid (florbetaben) and tau (PI‐2620 or MK‐6240) PET MRI, with composite SUVR calculated by averaging key cortical regions. Multivariable linear regression models tested the association of ESS and covariates (GDS, amyloid SUVR, tau SUVR, race) to the three CCI outcome measures (total, non‐amnestic, amnestic).ResultESS (excessive sleepiness) was significantly positively associated with total CCI (p = 0.01042) as well as non‐amnestic (0.00771) and amnestic CCI subgroups (0.02583), after full covariate adjustment, as was GDS. Race did not show an independent statistically significant association.ConclusionThese results suggest that excessive sleepiness, independent of depression and amyloid and tau burdens, may be a significant contributor to SCD severity. Furthermore, these contributions impact both amnestic and non‐amnestic domains. Future studies are needed to investigate the longitudinal impact of excessive sleepiness on SCD outcomes.

01 Dec 2024·Alzheimer's & Dementia

Unusually young onset of spastic paraparesis in a carrier of both the A431E PSEN1 and A713T APP variants

Article

Author: Ringman, John M ; Islas, Miguel Angel Macias ; Villareal, Enrique Israel Velazquez ; Sheikh‐Bahaei, Nasim ; Craig, David

AbstractBackgroundThe ways in which diverse genetic variants interact to affect the phenotype of AD is poorly understood. The relatively consistent phenotype associated with specific mutations causing autosomal dominant AD (ADAD) provides the opportunity to study how other genetic variants contribute to disease manifestations.MethodWe performed an in‐depth case study of a patient with the A431E PSEN1 mutation who had onset of progressive spastic paraplegia at age 20.ResultThe proband was a Mexican woman known to be at 50% risk for inheriting the A431E PSEN1 mutation that commonly presents with cognitive changes and/or spastic paraplegia at age 40. At age 20 she began developing stiffness in her legs and difficulty walking. When seen at age 26 she had diffuse spasticity worse in the legs, slurred speech, and was cognitively intact. A flortaucipir PET scan at the time was negative as was a florbetaben scan 21 months later despite marked differences from controls in DTI measures in the corticospinal tract. Genetic screening demonstrated the presence of the A431E PSEN1 mutation and an A713T APP variant which was confirmed by WGS. The A713T APP variant was not present in her mother who had more typical disease nor in 62 other persons of Mexican origin.ConclusionThe A713T variant in APP has been shown to affect APP processing and Abeta nucleation and is considered to be a risk factor for AD. We hypothesize that the presence of this variant led to the early onset of spastic paraparesis in our proband despite Abeta deposition in brain being undetectable on PET. This finding suggests spastic paraplegia may be related to aberrant APP processing in a manner distinct from plaque formation.This study was funded by R01AG062007 and R01AG069013

01 Aug 2024·Alzheimer's & Dementia

Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation

Article

Author: Younes, Kyan ; Mormino, Elizabeth C. ; Poston, Kathleen L. ; Zaharchuk, Greg ; Vossler, Hillary A. ; Carlson, Mackenzie L. ; Rathmann‐Bloch, Julia ; Henderson, Victor ; Harrison, Theresa M. ; Zeineh, Michael ; Wagner, Anthony ; Winer, Joseph R. ; Landau, Susan ; Sha, Sharon J. ; Young, Christina B. ; Davidzon, Guido A. ; Smith, Viktorija ; Johns, Emily ; Park, Jennifer

AbstractINTRODUCTIONAmyloid positron emission tomography (PET) acquisition timing impacts quantification.METHODSIn florbetaben (FBB) PET scans of 245 adults with and without cognitive impairment, we investigated the impact of post‐injection acquisition time on Centiloids (CLs) across five reference regions. CL equations for FBB were derived using standard methods, using FBB data collected between 90 and 110 min with paired Pittsburgh compound B data. Linear mixed models and t‐tests evaluated the impact of acquisition time on CL increases.RESULTSCL values increased significantly over the scan using the whole cerebellum, cerebellar gray matter, and brainstem as reference regions, particularly in amyloid‐positive individuals. In contrast, CLs based on white matter–containing reference regions decreased across the scan.DISCUSSIONThe quantification of CLs in FBB PET imaging is influenced by both the overall scan acquisition time and the choice of reference region. Standardized acquisition protocols or the application of acquisition time–specific CL equations should be implemented in clinical protocols.Highlights

Acquisition timing affects florbetaben positron emission tomography (PET) scan quantification, especially in amyloid‐positive participants.

The impact of acquisition timing on quantification varies across common reference regions.

Consistent acquisitions and/or appropriate post‐injection adjustments are needed to ensure comparability of PET data.

News (Medical) associated with Florbetaben F-18

13 Jan 2025

·endpts.com

Lantheus to buy Life Molecular Imaging for $350M, netting Alzheimer's diagnostic

Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its commercial Alzheimer’s diagnostics business. In addition to the $350 million upfront payment, the deal includes up to $400 million in potential earnout and milestone payments. Six months ago, Lantheus made a deal with Life Molecular Imaging to license a diagnostic and therapeutics pair of radiopharmaceuticals, both of which target a protein called gastrin-releasing peptide receptor that’s highly expressed in breast and prostate cancer. Lantheus’ top-selling drug is a radioactive agent used to diagnose prostate cancer called Pylarify. Lantheus is gaining five assets from the buyout, namely a commercial Alzheimer’s diagnostic agent called Neuraceq. It’s an area that Lantheus has been investing in, though previous acquisitions were for experimental agents. In July, Lantheus bought Meilleur Technologies and its experimental beta amyloid PET imaging agent called NAV-4694. In 2023, Lantheus bought Cerveau Technologies for its experimental tau-targeted PET imaging agent known as MK-6240. “This puts us squarely in the Alzheimer’s space a whole lot earlier — at least a year earlier — than we were planning with the launch of [MK-6240], and we’ve got a ready-[to]-go franchise,” CEO Brian Markison said.

AcquisitionDiagnostic Reagents

06 Jan 2025

·www.prnewswire.com

Life Molecular Imaging and SOFIE announce Neuraceq® availability in Somerset, NJ

Improved supply capabilities of Neuraceq® to provide better patient access to amyloid PET BOSTON, Jan. 6, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), an international pharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging, and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE's radiopharmaceutical manufacturing site located in Somerset, NJ. This agreement results in increased availability of Neuraceq® for imaging centers, physicians, and patients with cognitive impairment in eastern Pennsylvania, New Jersey, and New York. The first doses have been made available on January 3rd, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases. "LMI is devoted to expanding access to Neuraceq® for patients and physicians seeking confirmation of amyloid plaque in the brain, particularly for patients who are being evaluated for AD and may qualify for newly approved therapeutics. By increasing Neuraceq® manufacturing capabilities in Somerset, NJ, in partnership with SOFIE, we are strengthening our efforts to meet the growing demand for amyloid PET imaging. This initiative underscores our devotion to enhancing patient access and supporting the medical and patient communities in this important area of healthcare," said Colleen Ruby, US Country Head, and Chief Operating Officer, Americas and APAC. "SOFIE is proud to support the AD community through the manufacture and dispensing of Neuraceq®. With the continued growth in amyloid targeting therapies, the diagnosis and staging using PET is more important than ever. We are excited to partner with LMI to continue rapidly increasing access to this important diagnostic tool," said Brian Schumer, PharmD, SOFIE Chief Operating Officer. About Neuraceq® (florbetaben 18F) Indication Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Neuraceq® scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq® scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD and may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq® is an adjunct to other diagnostic evaluations. Limitations of Use A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder. Safety and effectiveness of Neuraceq® have not been established for: Predicting development of dementia or other neurologic conditions Monitoring responses to therapies. Important Safety Information Risk for Image Interpretation and Other Errors Errors may occur in the Neuraceq® estimation of brain neuritic β-amyloid plaque density during image interpretation. Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Neuraceq® images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq® scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq® scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future. Radiation Risk Neuraceq®, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure. Adverse Reactions The overall safety profile of Neuraceq® is based on data from 1,090 administrations of Neuraceq® to 872 subjects. No serious adverse reactions related to Neuraceq® administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq® were injection site reactions consisting of erythema (1.7%), irritation (1.1%) and pain (3.4%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI) is an international radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit . About Life Healthcare Group Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: | For media queries Brittany Hahn | Marketing Communications Manager | Life Molecular Imaging Tel: +1.484.735.2840 | [email protected] SOURCE Life Molecular Imaging WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/in

29 Oct 2024

·www.prnewswire.com

Life Molecular Imaging and PharmaLogic announce Neuraceq® availability in Cincinnati, OH

Improved supply capabilities of Neuraceq® to provide better patient access to beta-amyloid PET BOSTON, Oct. 29, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. (PharmaLogic), a world-class contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, announce their strategic partnership to provide and distribute Neuraceq® from PharmaLogic's radiopharmaceutical manufacturing site located in Cincinnati, OH. The first doses were made available on October, 24th, 2024. Neuraceq® is an FDA-approved imaging agent for the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases. "LMI is dedicated to focusing our activities on broadening Neuraceq® market access for patients and physicians who are seeking confirmation of beta-amyloid plaque in the brain, notably for individuals who may be eligible for therapeutics. Expanding Neuraceq® manufacturing in Cincinnati, OH, in collaboration with PharmaLogic, further reinforces our commitment to meeting the increased market demand for patient access to amyloid PET imaging with Neuraceq®. We are proud to support the medical and patient communities in this area," said Colleen Ruby, US Country Head, and Chief Operating Officer, Americas and APAC. James Beatty, VP of Development and Commercialization for PharmaLogic, highlighted the value of this partnership: "Our collaboration with Life Molecular Imaging enhances our ability to support the adoption of newly approved novel therapies for Alzheimer's disease by enabling a broad and reliable access to beta-amyloid PET providing these necessary diagnostics. Together, PharmaLogic is committed to delivering advanced diagnostic solutions that meet the needs of patients and clinicians in the Cincinnati, OH region." About Neuraceq (florbetaben 18F) Indication Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations. Limitations of Use A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder. Safety and effectiveness of Neuraceq have not been established for: Predicting development of dementia or other neurologic conditions Monitoring responses to therapies. Important Safety Information Risk for Image Interpretation and Other Errors Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation. Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future. Radiation Risk Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure. Common Adverse Reactions The overall safety profile of Neuraceq is based on data from 1,090 administrations of Neuraceq to 872 subjects. No serious adverse reactions related to Neuraceq administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema (1.7%), irritation (1.1%) and pain (3.4%). For more information please visit: neuraceq.com About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit . About Life Healthcare Group Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: | . For media queries Brittany Hahn | Marketing Communications Manager | Life Molecular Imaging Tel: +1.484.735.2840 | [email protected] SOURCE Life Molecular Imaging WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Florbetaben F-18

External Link

KEGG	Wiki	ATC	Drug Bank
-	Florbetaben F-18	V09AX06	DB09148

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cognitive Dysfunction	NO	Life Molecular Imaging Ltd.	20 Feb 2014
Cognitive Dysfunction	EU	Life Molecular Imaging Ltd.	20 Feb 2014
Cognitive Dysfunction	LI	Life Molecular Imaging Ltd.	20 Feb 2014
Cognitive Dysfunction	IS	Life Molecular Imaging Ltd.	20 Feb 2014
Diagnostic agents	IS	Life Molecular Imaging Ltd.	20 Feb 2014
Diagnostic agents	LI	Life Molecular Imaging Ltd.	20 Feb 2014
Diagnostic agents	EU	Life Molecular Imaging Ltd.	20 Feb 2014
Diagnostic agents	NO	Life Molecular Imaging Ltd.	20 Feb 2014
Alzheimer Disease	CA	Isologic Innovative Radiopharmaceuticals Ltd.Startup	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	NDA/BLA	AU	Life Molecular Imaging Ltd.	01 Nov 2009
Alzheimer Disease	NDA/BLA	FR	Life Molecular Imaging Ltd.	01 Nov 2009
Alzheimer Disease	NDA/BLA	DE	Life Molecular Imaging Ltd.	01 Nov 2009
Immunoglobulin Light-Chain Amyloidosis	Phase 3	ES	Life Molecular Imaging Ltd.	13 Jan 2023
Alzheimer Disease	Phase 1	JP	Life Molecular Imaging Ltd.	01 Nov 2009
Cerebral Amyloid Angiopathy	Phase 1	US	Life Molecular Imaging Ltd.	01 Nov 2009
Cerebral Amyloid Angiopathy	Phase 1	DE	Life Molecular Imaging Ltd.	01 Nov 2009
Cerebral Amyloid Angiopathy	Phase 1	FR	Life Molecular Imaging Ltd.	01 Nov 2009
Cerebral Amyloid Angiopathy	Phase 1	JP	Life Molecular Imaging Ltd.	01 Nov 2009
Cerebral Amyloid Angiopathy	Phase 1	AU	Life Molecular Imaging Ltd.	01 Nov 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01222351 (CTgov)	Not Applicable	Alzheimer Disease \| Cognitive Dysfunction	161	BAY 94-9172 (Florbetaben)	lgachnggwd(bvydftkbgx) = kajqllbksw vuakjnzfhb (vvyqbqlvmh, spueiywwyr - pegcutunhk) View more	-	06 May 2024
NCT03744312 (CTgov)	Phase 1/2	Alzheimer Disease \| Inflammation	9	Florbetaben+11C-ER176 (Cognitive Impairment)	kznsflelda(tlkfldnavg) = rakvqdzswp oqbzwdglps (lwvmabckvu, kkcibbdxrw - bbftuchiun) View more	-	13 Sep 2023
				Florbetaben+11C-ER176 (No Cognitive Impairment)	kznsflelda(tlkfldnavg) = cufwtkgqtn oqbzwdglps (lwvmabckvu, omedgxykde - xxnhbolxuz) View more
AMYPAD Diagnostic and Patient Management Study (EANM2022)	Not Applicable	Memory Disorders amyloid burden	729	18f-florbetaben (FBB)	zwihbbvzea(lrcqdrmuva) = icqpivumlq hxsuzhjecn (aqzzhefagv, 17.87) View more	-	22 Sep 2022
				18f-flutemetamol (FTM)	zwihbbvzea(lrcqdrmuva) = puvppzalcy hxsuzhjecn (aqzzhefagv, 17.87) View more
EANM2021	Not Applicable	Plaque, Amyloid \| Periodontitis	-	18 F-Florbetaben (Absence of periodontal disease or mild periodontitis)	zvpbuhtfth(ucgyqcqupb) = dpmzfmyxpl tohdffrdzu (wfewfdmynr )	-	24 Sep 2021
SNMMI2020	Not Applicable	Plaque, Amyloid	-	18 F-Florbetaben (Young Healthy Controls (YHC))	mrxjbiibvn(zmvpnmnrib) = sjlauyjlye maevvpyzac (eyxlkqvjdv, 0.03)	-	15 May 2020
				18 F-Florbetaben (Subjective Cognitive Decline (SCD))	vmolehkwoe(dncpfvsvty) = napxygjcvf azbfdtpszx (fxfpybytcm, 2.1) View more
EANM2019	Not Applicable	-	6	[18F]Florbetaben (Standard PET images)	jzlfjolwri(zjwhacrned) = wjixujgpbj nsryfnlxui (tphmkxmlja ) View more	-	18 Sep 2019
				[18F]Florbetaben (PET images with superimposed WM/GM boundaries)	(zvdafswwqy) = goetgmweij eoblchqoeu (penlazgifu ) View more
EANM2019	Not Applicable	Peroxisomal Disorders gene defect \| very long chain fatty acids (VLVFA)	4	[18F]Florbetaben (X-linked adulthood cerebral adrenoleukodystrophy (X-ACALD) patients)	teatvzfbks(blbpcauqew) = 9.8 ± 2.6 vllcxxuqxl (eyuhvddvbq ) View more	-	18 Sep 2019
				[18F]Florbetaben (Healthy control group)
EANM2018	Not Applicable	-	44	18F-Florbetaben (Amyloid-PET)	vznsiweppq(nyypmbzfjt) = gfpufzyegw qzceffuigr (ldelgmwhnt )	Positive	18 Sep 2018
AAIC2018	Not Applicable	Mild dementia \| Mild cognitive disorder ApolipoproteinE (APOE) genotype	152	[F-18] FLORBETABEN (Cognitively Normal)	dozivwivhq(yqpcewdegg) = fxhdrwswfq lcsogzqvza (hzjmrgrfki )	-	01 Jul 2018
				[F-18] FLORBETABEN (Mild Cognitive Impairment)	dozivwivhq(yqpcewdegg) = skypvpckdh lcsogzqvza (hzjmrgrfki )
EANM2017	Not Applicable	amyloid-positive \| amyloid-negative	107	18F-FlorbetabenFDG-Florbetaben (FDG-PET)	cgzuocykuf(ybsjhwmmvc) = dekjcdmqoh noirzorumm (ztbpaqqqvm )	Positive	11 Sep 2017
				18F-Florbetaben (FBB-PET)	cgzuocykuf(ybsjhwmmvc) = wmpvongmks noirzorumm (ztbpaqqqvm )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis